MedPath

Thermosensitive Gels for the Vaginal Delivery of Sildenafil Citrate

Phase 2
Completed
Conditions
Infertility
Interventions
Registration Number
NCT02766725
Lead Sponsor
Assiut University
Brief Summary

The aim of this study was to develop and characterize in situ thermosensitive gels for the vaginal administration of sildenafil as a potential treatment of the endometrial thinning that occurs as a result of the use of clomiphene citrate in induction of ovulation in women with World Health Organization type II EU gonadotrophic anovulation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
90
Inclusion Criteria
  • women with polycystic ovaries
Exclusion Criteria
  • women with other causes of infertility

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
preparation F12 sildenafil in-situ gel grouppreparation F12 sildenafil in situ gelwomen received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F12 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
preparation F2 sildenafil in-situ gel grouppreparation F2 sildenafil in situ gelwomen received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F2 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
placebo gel groupplacebo gelwomen received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + placebo gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator
Primary Outcome Measures
NameTimeMethod
The change of Doppler resistance index after the treatment10 days
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath